MedPath

To observe Haemophilia patients for control of external bleeding by using VELSEAL-T

Not Applicable
Completed
Conditions
Health Condition 1: null- Haemophilia Patients with External BleedingHealth Condition 2: D66- Hereditary factor VIII deficiency
Registration Number
CTRI/2017/10/009966
Lead Sponsor
Dr Anupam Dutta
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
48
Inclusion Criteria

1. Patients above 18 years of age with haemophilia disorders who require haemostasis control.

2. Patients who can provide informed consent form in writing and medically in a position to undergo consent for data collection.

3. Subjects willing and able to comply with the requirements of the study protocol, including the predefined follow-up evaluations.

Exclusion Criteria

1. Subjects with medical emergency, where treatment is the priority than the informed consent process and his/her representative deny to participant in the study.

2. Subjects who cannot provide the informed consent such as unconscious subjects.

3. The subjects who have been treated with other higher treatment for Haemorrhage control such as Tourniquets for more than 2 hours, Blood or platelet-rich-plasma transfusion etc.

4. Subjects with known possible loss of plasma or blood from other areas than wound such as lacerations, Uterine bleeding, Gastro-intestinal bleeding etc.

5. Subjects with an active infection at the injury site.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To observe the hemostatic efficacy of VELSEAL-T on haemophilia subjects with external bleeding to control haemorrhage.Timepoint: 12 minutes
Secondary Outcome Measures
NameTimeMethod
1. Assessment of number of VELSEAL-T-T used on a single wound until complete haemostasis. <br/ ><br>2. Assessment of VELSEAL-T related adverse events. <br/ ><br>3. To evaluate average time taken after application of VELSEALââ?¬â??T to control haemorrhage. <br/ ><br>4. Assessment of VELSEAL-T device w.r.t available options.Timepoint: 4 hours
© Copyright 2025. All Rights Reserved by MedPath